

Information Governance Department
Suite 9
Buckingham Row
Brick Kiln Lane
Wigan
WN1 1XX

Email: foi@wwl.nhs.uk
Web: www.wwl.nhs.uk

Ref: FOI/2023/9369

Date Received: 6th November 2023

Response Due: 4th December 2023

Date: 30th November 2023

Dear Sir/Madam

With reference to your request for information received on 6th November 2023, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

Patients with acute myeloid leukaemia (AML)

1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?

- **Azacitidine monotherapy**
5
- **Low dose cytarabine (LoDAC) monotherapy**
0
- **Venetoclax + azacitidine**
5
- **Venetoclax + LoDAC**
<5
- **Ivosidenib**
0
- **Intensive chemotherapy-based regimen**
0
- **Other**
0

Refusal Notice: Sec 40(2) Personal Information

The Trust has a policy of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

- a) Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and
- b) Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA).

2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?

Note: this should only include patients who have started first-line treatment during the 6-month window

- **Azacitidine monotherapy**
0
- **Low dose cytarabine (LoDAC) monotherapy**
0
- **Venetoclax + azacitidine**
<5
- **Venetoclax + LoDAC**
0
- **Ivosidenib**
0
- **Intensive chemotherapy-based regimen**
0
- **Other**
0

Refusal Notice: Sec 40(2) Personal Information

The Trust has a policy of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

- a) Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and
- b) Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA).

3. (a) Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many are approved for treatment via Blueteq?

All patients were approved on blueteq who received venetoclax as part of their treatment.

Patients with chronic lymphocytic leukaemia (CLL)

4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include patients who started treatment prior to the 6-month window

7

5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

Note: this should include only patients who have started treatment during the 6-month window

<5

Refusal Notice: Sec 40(2) Personal Information


The Trust has a policy of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

- a) Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and
- b) Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA).

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,



Gary Masterman
Associate Director of Pharmacy

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111